Skip to main content
Livzon Pharmaceutical Group Inc. logo

Livzon Pharmaceutical Group Inc. — Investor Relations & Filings

Ticker · 1513 LEI · 529900Y4GWTVVTORJ443 HKEX Manufacturing
Open in API
Filings indexed 2,605 across all filing types
Latest filing 2026-04-10 Regulatory Filings
Country CN China
Listing HKEX 1513

About Livzon Pharmaceutical Group Inc.

http://www.livzon.com.cn

Livzon Pharmaceutical Group Inc., established in 1985, is a comprehensive pharmaceutical enterprise integrating the research, development, production, and sales of finished pharmaceutical products and Active Pharmaceutical Ingredients (API). The Group maintains a strong focus on therapeutic areas such as digestive health, reproductive endocrinology, and immune diseases. Committed to product quality, Livzon implements a rigorous quality management system to ensure the effectiveness, safety, and stability of its portfolio.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT THE NOTICE OF DRUG CLINICAL TRIAL APPROVAL OF JP-1366 TABLET
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement regarding the approval of a clinical trial by a regulatory authority (NMPA). It is not a financial report, dividend notice, or detailed investor presentation, nor is it an AGM or earnings release. It does not fit any specialized category (e.g., M&A, ESG, management change). Therefore it falls under the general “Regulatory Filings” (RNS) fallback category for miscellaneous corporate regulatory announcements.
2026-04-10 English
Date of Board Meeting
Regulatory Filings Classification · 1% confidence The document is a brief announcement by Livzon Pharmaceutical Group Inc. regarding the date of a Board meeting to consider and approve its unaudited quarterly results. It does not contain the results themselves nor any change of board members, dividend information, or any detailed report. It simply notifies the market of an upcoming board meeting, which does not match any more specific category. Therefore it falls under the fallback category of general regulatory announcements (RNS).
2026-04-08 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 1% confidence The document is extremely short and merely states that an announcement has been published elsewhere (Chinese section of the website) without providing any substantive content or detailed financial information. This fits the ‘Report Publication Announcement’ category, which covers notices that reports or announcements have been published or attached. Therefore, the appropriate classification is RPA.
2026-04-01 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 March 2026
Regulatory Filings Classification · 1% confidence The document is a routine monthly return (Form FF301) filed with the Hong Kong Stock Exchange detailing movements in the issuer’s authorised share capital, issued shares, public float confirmation, and related compliance confirmations. It is a regulatory submission and does not fit into specific categories like share issue announcements (no actual change), dividends, or management changes. Therefore, it falls under the general “Regulatory Filings” fallback category.
2026-04-01 English
SUPPLEMENTAL ANNOUNCEMENT ON THE PROPOSED PROFIT DISTRIBUTION PLAN FOR THE YEAR ENDED 31 DECEMBER 2025
Notice of Dividend Amount Classification · 1% confidence The document is a supplemental announcement relating to the Company’s proposed profit distribution plan (i.e., dividend) for the year ended 31 December 2025. It details the cash dividend amount (RMB14.30 per 10 shares), clarifies there will be no bonus shares or capitalisation of reserves, and requests shareholder approval. These characteristics match a Notice of Dividend Amount filing (DIV).
2026-03-26 English
VOLUNTARY ANNOUNCEMENT THE NOTICE OF DRUG CLINICAL TRIAL APPROVAL OF BREXPIPRAZOLE MICROSPHERES
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement filed on the Hong Kong Stock Exchange announcing that the company’s subsidiary has received clinical trial approval from China’s National Medical Products Administration. It contains no financial results, board changes, dividend notices, share issuances, or other specific events (M&A, financing, etc.). It is a general regulatory announcement regarding product development approval. No more specific category applies, so it falls into the fallback “Regulatory Filings” category (Code: RNS).
2026-03-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.